BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/10/2020 7:36:26 AM | Browse: 1217 | Download: 2852
 |
Received |
|
2019-10-11 11:38 |
|
Peer-Review Started |
|
2019-10-11 11:38 |
|
First Decision by Editorial Office Director |
|
2019-11-01 22:03 |
|
Return for Revision |
|
2019-11-05 00:24 |
|
Revised |
|
2019-12-23 15:06 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-01-13 10:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-01-13 21:39 |
|
Articles in Press |
|
2020-01-13 21:39 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-01-16 09:05 |
|
Publish the Manuscript Online |
|
2020-02-10 07:36 |
| Category |
Critical Care Medicine |
| Manuscript Type |
Observational Study |
| Article Title |
Experience with hemoadsorption (CytoSorb<sup>®</sup>) in the management of septic shock patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yatin Mehta, Chitra Mehta, Ashish Kumar, Joby V George, Aditi Gupta, Saurabh Nanda, Gaurav Kochhar and Arun Raizada |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yatin Mehta, FRCA, MD, MNAMS, Doctor, Doctor, Institute of Critical care and Anesthesia, Medanta The Medicity, Sector 38, Gurgaon 122006, Haryana, India. yatin.mehtacriticalcare@gmail.com |
| Key Words |
Hemoadsorption; Sepsis; Cytokines; Clinical conditions; Inflammation and extracorporeal; |
| Core Tip |
CytoSorb® is a promising new extracorporeal cytokine hemoadsorption device that can modulate the cytokine storm during sepsis. This retrospective study evaluated clinical outcomes after CytoSorb® therapy of 100 patients admitted to intensive care unit with sepsis. We observed a significant reduction in vasopressors dosage in 40 patients who survived. The survivors also had a reduction in all the biomarker levels (procalcitonin, C-reactive protein, serum lactate and bilirubin) and inflammatory markers (interleukin 6, interleukin 10 and tumour necrosis factor) after CytoSorb® therapy. Notably, 28% of patients who were given CytoSorb® therapy < 48 h after onset of septic shock survived. |
| Publish Date |
2020-02-10 07:36 |
| Citation |
Mehta Y, Mehta C, Kumar A, George JV, Gupta A, Nanda S, Kochhar G, Raizada A. Experience with hemoadsorption (CytoSorb®) in the management of septic shock patients. World J Crit Care Med 2020; 9(1): 1-12 |
| URL |
https://www.wjgnet.com/2220-3141/full/v9/i1/1.htm |
| DOI |
https://dx.doi.org/10.5492/wjccm.v9.i1.1 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
